Immune Thrombocytopenia (ITP) Market Size, Share & Industry Analysis, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Regional Forecast, 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Immune Thrombocytopenia (ITP) Market with respect to COVID-19 Business Impact.
Inquire before buying

This report focuses on the Immune Thrombocytopenia (ITP) market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Immune Thrombocytopenia (ITP) market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Immune Thrombocytopenia (ITP) Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Immune Thrombocytopenia (ITP) Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Immune Thrombocytopenia (ITP) Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Key Market Players Like Amgen Inc., Novartis AG, and CSL Limited will Ensure to Reinforce the Market Position concerning Providing Immune Thrombocytopenia treatment worldwide.

The immune thrombocytopenia treatment market is an extremely consolidated market since the top 3 players hold a considerable share of the market. As of 2018, Novartis AG is leading the player in the global ITP market. Amgen Inc. is strengthening its strategic position in the global immune thrombocytopenia market by extending the indication of the companys Nplate which is recently indicated for prescription if children suffering from chronic ITP. This company, together with Novartis AG currently holds more than half of the market share in terms of revenue. Other players operating in the global idiopathic thrombocytopenic purpura market are Grifols S.A, Rigel Pharmaceuticals, Inc., and Others.

LIST OF KEY COMPANIES PROFILED:

 	
Amgen Inc.
 	
Novartis AG
 	
Rigel Pharmaceuticals, Inc.
 	
Dova Pharmaceuticals
 	
Grifols S.A
 	
CSL Limited
 	
Octapharma AG
 	
Intas Pharmaceuticals Ltd.
 	
Saol Therapeutics

REPORT COVERAGE

The research report offers an in-depth analysis of the immune thrombocytopenia market. It further provides details on the adoption of immune thrombocytopenia treatment drugs across several regions. Information on trends, drivers, opportunities, threats, and restraints of the market can further help stakeholders to gain valuable insights into the market. The report offers a detailed competitive landscape by presenting information on key players, along with their strategies, in the market.

Along with this, the report provides an elaborative analysis of the global market dynamics and competitive landscape. Various key insights provided in the report are key industry developments- partnerships, mergers and acquisitions, the prevalence of immune thrombocytopenia for key countries, pipeline analysis, patent analysis, and introduction of new products / approvals (by major players).

Report Scope & Segmentation:

 Segmentation

By Type

 	
Acute Immune Thrombocytopenia
 	
Chronic Immune Thrombocytopenia

By Treatment

 	
Thrombopoietin Receptor Agonist
 	
Immunoglobulins
 	
Corticosteroids
 	
Others

By Distribution Channel

 	
Hospital Pharmacy
 	
Retail Pharmacy
 	
Others

By Region/Country

 	
North America (U.S. and Canada)
 	
Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe)
 	
Asia Pacific (Japan, China, India, South Korea, Australia, and Rest of Asia Pacific)
 	
Latin America
 	
Middle East and Africa

INDUSTRY DEVELOPMENT:

In Jan 2020, Instituto Grifols S.A. received marketing authorization valid throughout the European Union for Tavlesse which is a medicine for treating adults with chronic immune thrombocytopenia. It is for use when other treatments have not worked.

Chronic immune thrombocytopenia, previously called idiopathic thrombocytopenic purpura (ITP), is a long-term condition in which the immune system (the body’s defences) destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding. Patients with the disease have low platelet counts and may bruise or bleed easily.

Tavlesse contains the active substance fostamatinib.

March 2018: Dova Pharmaceuticals, along with its wholly-owned subsidiary AkaRx, Inc. entered into a distribution and development rights agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. For DOPTELET in China and Hong Kong.

April 2018: U.S Food and Drug Administration (FDA) approved the therapeutic use of TAVALISSE developed by Rigel Pharmaceuticals, Inc. as the second line of treatment for ITP.

March 2015: Novartis AG entered into a business acquisition agreement to acquire oncology products and pipeline compounds under development by GlaxoSmithKline plc. This transaction included a recently launched product named Promacta indicated to treat immune thrombocytopenia.

February 2019: Paras Biopharmaceuticals Finland Oy announced the successful development of biologically active Romiplostim